Outcome of secondary myeloid malignancy in Hodgkin's disease: The BNLI experience

European Journal of Haematology

Volumn 61, Issue 2, 1998, Pages 109-112

  Harrison, Claire N ^b   Hudson, Gillian Vaughan ^a   Devereux, Stephen ^b   Linch, David C ^b  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hodgkin's disease; Outcome and BNLI; Secondary MDS AML

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; PROGNOSIS; SECOND CANCER;

EID: 0031830862     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01069.x     Document Type: Article

References (13)

1. TUBIANA M, HENRY-AMAR M, CARDE P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clincal trials: 1964-1987. Blood 1989: 73: 47-56.
2. DEVEREUX S, SELASSIE TG, VAUGHAN HUDSON G, VAUGHAN HUDSON B, LINCH DC. Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. Br Med J 1990: 301: 1077-1080.
3. SWERDLOW AJ, DOUGLAS AJ, VAUGHAN HUDSON G, VAUGHAN HUDSON B, MACLENNAN KA. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology, and stage of Hodgkin's disease and splenectomy. Br J Cancer 1993: 68: 1006-1011.
4. CADMAN EC, CAPIZZI RL, BERTINO JR. Acute nonlymphocytic leukaemia: a delayed complication of Hodgkin's disease therapy: analysis of 109 cases. Cancer 1977: 40: 1280-1296.
5. MICHELS SD, MCKENNA RW, ARTHUR DC, BRUNNING RD. Therapy-related acute myeloid leukaemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood 1985: 65: 1364-1372.
6. LARSON RA, WERNLI M, LE BEAU MM, et al. Short remission duration in therapy-related leukaemia despite cytogenetic complete responses to high-dose cytarabine. Blood 1988: 72: 1333-1339.
7. PEDERSEN-BJFRGAARD J, LARSEN SO, STRUCK J, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease: relation to age, cumulative dose of alkylating agents and time from chemotherapy. Lancet 1987: II: 83-88.
8. LACHER MJ, SUSMAN LN. Leukaemia and Hodgkin's disease. Ann Intern Med 1963: 59: 369-378.
9. CHOPRA R, MCMILLAN AK, LINCH DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-centre eight year study of 155 patients. Blood 1993: 81: 1137-1145.
10. LINCH DC, WINFIELD D, GOLDSTONE AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993: 341: 1051-1054.
11. STONE RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress? Blood 1994: 83: 3437-3440.
12. HARRISON CN, VAUGHAN HUDSON G, PERRY A, et al. BEAM and ABMT/PBSCT may reduce the risk of secondary leukaemia in Hodgkin's disease: a case control analysis with the BNLI database. Blood 1996: 88 (suppl 1): 262a.
13. ANDERSON JE, GOOLEY TA, SCHOCH G, et al. Stem cell transplantation for secondary acute myeloid leukaemia: evalaution of transplantation as initial therapt or following induction chemotherapy. Blood 1997: 89: 2578-2585.